Dr Reddy's Laboratories EBIT 2010-2024 | RDY

Dr Reddy's Laboratories annual and quarterly EBIT history from 2010 to 2024. EBIT can be defined as earnings before interest and taxes.
  • Dr Reddy's Laboratories EBIT for the quarter ending June 30, 2024 was $0.215B, a 0% increase year-over-year.
  • Dr Reddy's Laboratories EBIT for the twelve months ending June 30, 2024 was $812M, a 7.41% increase year-over-year.
  • Dr Reddy's Laboratories 2024 annual EBIT was $0.812B, a 16.83% increase from 2023.
  • Dr Reddy's Laboratories 2023 annual EBIT was $0.695B, a 78.66% increase from 2022.
  • Dr Reddy's Laboratories 2022 annual EBIT was $0.389B, a 13.36% decline from 2021.
Dr Reddy's Laboratories Annual EBIT
(Millions of US $)
2024 $812
2023 $695
2022 $389
2021 $449
2020 $435
2019 $302
2018 $183
2017 $208
2016 $447
2015 $422
2014 $435
2013 $355
2012 $365
2011 $258
2010 $223
2009 $-79
Dr Reddy's Laboratories Quarterly EBIT
(Millions of US $)
2024-06-30 $215
2024-03-31 $175
2023-12-31 $207
2023-09-30 $215
2023-06-30 $215
2023-03-31 $139
2022-12-31 $200
2022-09-30 $202
2022-06-30 $154
2022-03-31 $11
2021-12-31 $125
2021-09-30 $164
2021-06-30 $90
2021-03-31 $106
2020-12-31 $112
2020-09-30 $123
2020-06-30 $108
2020-03-31 $112
2019-12-31 $103
2019-09-30 $104
2019-06-30 $116
2019-03-31 $82
2018-12-31 $80
2018-09-30 $72
2018-06-30 $68
2018-03-31 $40
2017-12-31 $78
2017-09-30 $59
2017-06-30 $6
2017-03-31 $55
2016-12-31 $85
2016-09-30 $51
2016-06-30 $17
2016-03-31 $68
2015-12-31 $115
2015-09-30 $143
2015-06-30 $121
2015-03-31 $132
2014-12-31 $115
2014-09-30 $89
2014-06-30 $104
2014-03-31 $88
2013-12-31 $129
2013-09-30 $118
2013-06-30 $63
2013-03-31 $100
2012-12-31 $75
2012-09-30 $113
2012-06-30 $70
2012-03-31 $163
2011-12-31 $142
2011-09-30 $43
2011-06-30 $66
2011-03-31 $39
2010-12-31 $62
2010-09-30 $87
2010-06-30 $53
2010-03-31 $-17
2009-12-31 $55
2009-09-30 $54
2009-06-30 $69
2009-03-31 $188
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $12.521B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00